The incidence of atypical fibroxanthoma and pleomorphic dermal sarcoma in Denmark from 2002 to 2022

IF 2.3 4区医学 Q3 ONCOLOGY

Surgical Oncology-Oxford Pub Date : 2024-09-26 DOI:10.1016/j.suronc.2024.102147

Olivia Fruergaard, Mathias Ørholt, Peter Viktor Vester-Glowinski, David Hebbelstrup Jensen

{"title":"The incidence of atypical fibroxanthoma and pleomorphic dermal sarcoma in Denmark from 2002 to 2022","authors":"Olivia Fruergaard, Mathias Ørholt, Peter Viktor Vester-Glowinski, David Hebbelstrup Jensen","doi":"10.1016/j.suronc.2024.102147","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The purpose of this study was to assess trends in the incidence rates and overall survival of atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) in the Danish population from 2002 to 2022.</div></div><div><h3>Methods</h3><div>We included all patients diagnosed with AFX or PDS in the Danish National Pathology Register (DNPR) during the study period. We computed the age-adjusted incidence rate (AAIR) per 100,000 and the average annual percent change (AAPC) and developed an age-period-cohort (APC) model of incidence.</div></div><div><h3>Results</h3><div>We included a total of 1118 patients, 78.3 % of whom were men. The median age upon diagnosis for AFX and PDS was 77.6 and 78.4 years, respectively. 84.5 % of the 1118 patients received an AFX diagnosis, while 15.5 % received a PDS diagnosis. The AAIR rose from 0.2 per 100,000 individuals in 2002 to 0.5 per 100,000 by 2022, with a peak increase of 0.75 per 100,000 in 2014. The AAPC for both tumors was 5.3 (95 % CI 2.9 %–7.7 %). We found a significant difference in overall survival between AFX and PDS, with PDS having worse overall survival than AFX.</div></div><div><h3>Conclusion</h3><div>This study, which included the largest non-selected national population to date, found a significant increase in the incidence of AFX and PDS between 2002 and 2015, followed by a decrease.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Oncology-Oxford","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960740424001154","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The purpose of this study was to assess trends in the incidence rates and overall survival of atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) in the Danish population from 2002 to 2022.

Methods

We included all patients diagnosed with AFX or PDS in the Danish National Pathology Register (DNPR) during the study period. We computed the age-adjusted incidence rate (AAIR) per 100,000 and the average annual percent change (AAPC) and developed an age-period-cohort (APC) model of incidence.

Results

We included a total of 1118 patients, 78.3 % of whom were men. The median age upon diagnosis for AFX and PDS was 77.6 and 78.4 years, respectively. 84.5 % of the 1118 patients received an AFX diagnosis, while 15.5 % received a PDS diagnosis. The AAIR rose from 0.2 per 100,000 individuals in 2002 to 0.5 per 100,000 by 2022, with a peak increase of 0.75 per 100,000 in 2014. The AAPC for both tumors was 5.3 (95 % CI 2.9 %–7.7 %). We found a significant difference in overall survival between AFX and PDS, with PDS having worse overall survival than AFX.

Conclusion

This study, which included the largest non-selected national population to date, found a significant increase in the incidence of AFX and PDS between 2002 and 2015, followed by a decrease.

查看原文本刊更多论文

2002 年至 2022 年丹麦非典型纤维黄瘤和多形性真皮肉瘤的发病率。

背景：本研究旨在评估2002年至2022年丹麦人口中非典型纤维黄瘤（AFX）和多形性真皮肉瘤（PDS）的发病率和总生存率的变化趋势：我们纳入了研究期间丹麦国家病理登记册（DNPR）中所有确诊为AFX或PDS的患者。我们计算了每十万人的年龄调整发病率（AAIR）和年均百分比变化率（AAPC），并建立了发病率的年龄-时期-队列（APC）模型：我们共纳入了 1118 名患者，其中 78.3% 为男性。AFX和PDS的诊断年龄中位数分别为77.6岁和78.4岁。在 1118 名患者中，84.5% 被诊断为 AFX，15.5% 被诊断为 PDS。AAIR从2002年的每10万人中0.2人上升到2022年的每10万人中0.5人，2014年达到峰值，为每10万人中0.75人。两种肿瘤的 AAPC 均为 5.3（95 % CI 2.9 %-7.7%）。我们发现，AFX 和 PDS 的总生存率存在明显差异，PDS 的总生存率低于 AFX：这项研究包括了迄今为止最大的非选择性全国人口，发现2002年至2015年间AFX和PDS的发病率显著增加，随后有所下降。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgical Oncology-Oxford 医学-外科

CiteScore

4.50

自引率

0.00%

发文量

169

审稿时长

38 days

期刊介绍： Surgical Oncology is a peer reviewed journal publishing review articles that contribute to the advancement of knowledge in surgical oncology and related fields of interest. Articles represent a spectrum of current technology in oncology research as well as those concerning clinical trials, surgical technique, methods of investigation and patient evaluation. Surgical Oncology publishes comprehensive Reviews that examine individual topics in considerable detail, in addition to editorials and commentaries which focus on selected papers. The journal also publishes special issues which explore topics of interest to surgical oncologists in great detail - outlining recent advancements and providing readers with the most up to date information.